Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07489300 | Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer(BACON) | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT07483905 | Interest in Nighttime Day Hospital Chemotherapy Infusions Among Gynecologic Cancer Patients(CHeMoON) | not yet recruiting | — | 200 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| 1 |
| Mar 19, 2026 |
| clinicaltrials |
| NCT05479045 | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | not yet recruiting | Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07455071 | A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer(YS247) | not yet recruiting | N/A | 9 | Peking University Third HospitalOTHER | 0 | Mar 16, 2026 | clinicaltrials |
| NCT07462468 | A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer. | not yet recruiting | Phase 1 | 36 | WestVac Biopharma Co., Ltd.INDUSTRY | 0 | Mar 13, 2026 | clinicaltrials |
| NCT07466901 | A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer | not yet recruiting | N/A | 30 | Jin LIOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07461142 | Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers(RETHEMCOL) | not yet recruiting | N/A | 72 | Institut Paoli-CalmettesOTHER | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07454018 | Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07450963 | Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT | not yet recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 0 | Mar 5, 2026 | clinicaltrials |
| NCT07437326 | Food-related Quality of Life in Patients With Cancer(QVA-Mod) | not yet recruiting | — | 180 | Hospices Civils de LyonOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07432594 | Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer | not yet recruiting | Phase 2 | 82 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07429799 | An Exploratory Study of Detection of Endometrial and Ovarian Cancers in Vaginal Samples Retrieved by the Ellele Sampling Device | not yet recruiting | N/A | 300 | Ellele HealthINDUSTRY | 0 | Feb 24, 2026 | clinicaltrials |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | not yet recruiting | Phase 1 / Phase 2 | 24 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07420010 | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. | not yet recruiting | Early Phase 1 | 24 | Weijia Fang, MDOTHER | 0 | Feb 19, 2026 | clinicaltrials |
| NCT06900582 | SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in p53-Mutated Endometrial Cancer: A Non-Inferiority Randomized Trial(SENTIMETREP53) | not yet recruiting | N/A | 374 | University Hospital, Strasbourg, FranceOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07412873 | Study on Sexual Health and Self-perceived Quality of Life (PROMs) in Patients Treated for Cervical Cancer(PROVIDENCE) | not yet recruiting | Phase 4 | 120 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07406789 | Phase II, Prospective, Randomized, Proof-of-concept Study to Evaluate the Effects of a Personalized Dietary Intervention in Women With Advanced Gynecologic or Breast Tumors Treated With Antibody-Drug Conjugates (ADCs).(LUMInova) | not yet recruiting | Phase 2 | 100 | TNC Nutrición Terapéutica S.L.OTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407452 | Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 50 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07401654 | The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression | not yet recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07394413 | Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas(SHAFT) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07379905 | MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)(MODUCIN1) | not yet recruiting | N/A | 182 | Aristotle University Of ThessalonikiOTHER | 0 | Feb 5, 2026 | clinicaltrials |
| NCT07382479 | NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery(NACT-KELIM ID) | not yet recruiting | N/A | 485 | Aristotle University Of ThessalonikiOTHER | 0 | Feb 5, 2026 | clinicaltrials |
| NCT07164534 | A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.(CHOC-LATE) | not yet recruiting | Phase 3 | 316 | Tata Memorial HospitalOTHER_GOV | 0 | Feb 4, 2026 | clinicaltrials |
| NCT07385976 | The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients | not yet recruiting | — | 100 | Far Eastern Memorial HospitalOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07382713 | Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 43 | Jinhua ZhouOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07382505 | Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer | not yet recruiting | — | 600 | Asan Medical CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07378371 | Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium | not yet recruiting | N/A | 174 | Aerospace Center HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07374809 | IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER(DEMETER) | not yet recruiting | N/A | 50 | European Institute of OncologyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07286162 | Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer(CALM-TF) | not yet recruiting | Phase 3 | 300 | University Health Network, TorontoOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07368985 | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | not yet recruiting | Phase 2 | 87 | Prof. Dr. Remi A. NoutOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07369986 | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer(IMMUNE-SAVE) | not yet recruiting | Phase 2 | 30 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Jan 27, 2026 | clinicaltrials |
| NCT07370818 | To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer | not yet recruiting | Phase 2 | 81 | Onconic Therapeutics Inc.INDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07363330 | A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 32 | Zhongnan HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07362147 | Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life | not yet recruiting | N/A | 74 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07066969 | Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer(GerEC) | not yet recruiting | N/A | 20 | European Institute of OncologyOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07355010 | A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 104 | Qinglei GaoOTHER | 0 | Jan 21, 2026 | clinicaltrials |
| NCT07348861 | A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 25 | Zheng MinOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07240220 | The Mother-Daughter Project: Merck-4(Merck-4) | not yet recruiting | N/A | 2,500 | Indiana UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07333326 | Uterine Artery Doppler Flow Velocimetry Parameters for Predicting the Occurrence of Persistent Gestational Trophoblastic Neoplasia After Evacuation of Complete Hydatiform Mole | not yet recruiting | — | 175 | Minia UniversityOTHER | 0 | Jan 12, 2026 | clinicaltrials |
| NCT07321730 | Surgeons' Ability to Predict Pathological and Molecular Features of Peritoneal Carcinomatosis in Ovarian Cancer(Visual-PC) | not yet recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07318701 | Multi-agent LLMs for Decision Support in Cervical Cancer During Pregnancy | not yet recruiting | N/A | 150 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 0 | Jan 6, 2026 | clinicaltrials |
| NCT07306260 | Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2(PDT for CIN2) | not yet recruiting | N/A | 560 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06799624 | Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr(PREFACE) | not yet recruiting | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07298707 | Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up(EndoMethy-V) | not yet recruiting | — | 3,500 | Peking Union Medical College HospitalOTHER | 0 | Dec 23, 2025 | clinicaltrials |
| NCT07295132 | RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) | not yet recruiting | Phase 2 | 160 | Asan Medical CenterOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07271914 | PONDER: Pelvic Peritonectomy in Early Stage Ovarian Tumors(PONDER) | not yet recruiting | N/A | 390 | Ospedale Santa Croce-Carle CuneoOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07273396 | Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 53 | Seoul National University HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT05077215 | Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer | not yet recruiting | Phase 3 | 450 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT05106127 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | not yet recruiting | Phase 2 | 28 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 24, 2026source: clinicaltrials